
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 7, 2019

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35547
(Commission
File Number)

36-4392754
(IRS Employer
Identification No.)

**222 Merchandise Mart Plaza, Suite 2024,
Chicago, Illinois 60654**
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (800) 334-8534

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure

On January 7, 2019, the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. A copy of the Company's presentation is furnished as Exhibit 99.1. The Company intends to use this presentation at other investor conferences.

The information furnished pursuant to this Item shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 [Copy of Allscripts Healthcare Solutions, Inc. presentation slides](#)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: January 7, 2019

By: /s/ Brian P. Farley
Brian P. Farley
Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary



Allscripts Healthcare Solutions

JANUARY 2019

J.P. Morgan
Healthcare Conference



Disclaimer


This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements under “Financial Model and Long Term Outlook”. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made (or any other specified date), and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts actual results to differ materially from those described in the forward-looking statements include, but are not limited to: the anticipated growth of the Veradigm business; the expected financial contribution from businesses acquired by Allscripts, including the hospital and health systems business acquired from McKesson Corporation (the “EIS Business”), the provider/patient solutions business acquired from NantHealth, Practice Fusion and HealthGrid; the successful integration of businesses acquired by Allscripts; the anticipated and unanticipated expenses and liabilities related to the businesses acquired by Allscripts; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts failure to compete successfully; consolidation in Allscripts industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts or its customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts sales, services and support organizations; market acceptance of Allscripts products and services; the unpredictability of the sales and implementation cycles for Allscripts products and services; Allscripts ability to manage future growth; Allscripts ability to introduce new products and services; Allscripts ability to establish and maintain strategic relationships; risks related to the acquisition of new companies or technologies; the performance of Allscripts products; Allscripts ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts ability to hire, retain and motivate key personnel; performance by Allscripts content and service providers; liability for use of content; security breaches; price reductions; Allscripts ability to license and integrate third party technologies; Allscripts ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts business is contained in Allscripts filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in the most recent Allscripts Annual Report on Form 10-K and subsequent Form 10-Qs. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.

Allscripts Today: A Business Transformed


P A S T	P R E S E N T
Experienced leadership team	Longest tenured leadership team among public peers
Shift to subscription based revenue	~80% annual recurring revenue
Gaps in EHR solution set	Full EHR solution set
Increased leverage to drive strategic investments	De-risked balance sheet: leverage <2x post Netsmart sale
Complex financial reporting	Simplified reporting post Netsmart sale
Focus on provider end markets	Focus on provider and high growth payer and life sciences
Consolidator of EHR platforms	Increased scale to drive operating leverage and industry relevance
Investments in culture	High performance culture focused on client success and giving back

Strong Financial Performance (Excluding Netsmart)

NON-GAAP REVENUE



ADJUSTED EBITDA



Dollars in millions. See reconciliation of non-GAAP metrics in the appendix of this presentation and on the Allscripts investor relations website. 2018 estimates based on low end of 2018 outlook provided on November 1, 2018.


Copyright © 2019 Allscripts Healthcare Solutions, Inc.

History of Meeting Commitments

YEAR	NON-GAAP EPS GUIDANCE	ACTUAL NON-GAAP EPS	
2015	\$0.42 - \$0.50	\$0.47	
2016	\$0.55 - \$0.62	\$0.55	
2017	\$0.61 - \$0.63	\$0.62	

See reconciliation of non-GAAP metrics in the appendix of this presentation and on the Allscripts investor relations website.

Efficient Capital Deployment...



...Positioned Allscripts to be a Long-Term Winner

NO.	VENDOR	2018 EST. REVENUE (MIL)
1	Cerner	\$5,391
2	Epic (estimated)	\$2,700
3	Allscripts (ex-Netsmart)	~\$1,800
4	athenahealth	\$1,341
5	NextGen	\$530
6	MEDITECH	\$480
7	GE (owned by Veritas now)	\$450
8	eClinicalWorks (estimated)	\$450
9	Greenway (estimated)	\$350
10	CPSI	\$282

Source: Company filings, Nasdaq consensus estimates for CERN, ATHN, NXGN, CPSI as of 12/13/18, <https://www.healthcare-informatics.com/hci100/2018-hci-100-list>
 ~ Assumes low end of 2018 revenue guidance as provided on November 1, 2018, excluding Netsmart.

Copyright © 2019 Allscripts Healthcare Solutions, Inc.

Future Growth




Healthcare Provider Software and Services

Healthcare provider IT spending is projected to increase over the next 5 years, regardless of how the economy performs (shift from fee for service to value based)



HEALTHCARE PROVIDER GLOBAL IT SPENDING



Dollars in billions.
Source: Gartner

Copyright © 2019 Allscripts Healthcare Solutions, Inc.

EHRs are a Mature Market

What will providers be buying?

01

Consumer / Patient Engagement Solutions

02

Financial Decision Support Systems, Real-Time Resource Allocation

03

Care Coordination between Traditional and Post-Acute Care

04

Personalized Medicine Solutions

05

Predictive Analytics and Optimization Solutions

06

Revenue Cycle Solutions and Services

07

Basic Clinical and Practice Management Solutions outside the U.S.




Allscripts is Well Positioned in These Areas

AREAS	BEST IN CLASS	COMPETITIVE
Patient Engagement	✓	
Financial Decision Support	✓	
Care Coordination	✓	
Personalized Medicine	✓	
Predictive Analytics and Optimization		✓
Revenue Cycle Solutions and Services		✓
Clinical and Practice Management Solutions outside the U.S.		✓

Payer & Life Sciences Market Size & Growth

The payer & life sciences market is larger than the provider software market today, and growing at more than twice the rate




Source: Oliver Wyman

Copyright © 2019 Allscripts Healthcare Solutions, Inc.

Payer & Life Sciences End Markets are Growing Rapidly

What will these companies be buying?



Veradigm Core Solutions

We are far ahead of any other traditional EHR competitor in delivering value to these end markets



Data/Analytic & Research

- Analytics/Insights Services
- De-ID Data for Research
- Registries and Custom Data Capture



Clinical Workflow

- Promotional Messaging
- Rx Price Transparency and pre-authorizations
- Lab Network



Health Plan

- eChartCourier (Electronic Chart Retrieval)
- Payer Gaps in Care messaging and pre-authorizations
- Risk Adjustment Analytics



Financial Model and Long-Term Outlook



Top Line Growth Derived Across Our Different End Markets

3 Year (2019-2021) Non-GAAP Revenue CAGR

	3 YEAR (2019-2021) REVENUE CAGR	RELATIVE SIZE	WEIGHTED IMPACT
Provider	~2-4%	~90%	~2.0 – 3.5
Veradigm	~15-25%	~10%	~1.5 – 2.5
Organic Non-GAAP Revenue CAGR			3.5% – 6.0%
Non-Organic Non-GAAP Revenue CAGR			2.0% – 3.0%
Total Non-GAAP Revenue CAGR			5.5% – 9.0%

Investment Considerations

We enable providers, payers and life science companies to optimize value at the point of care



Robust, diversified and award winning solutions portfolio



Flexible balance sheet with capacity for investment and capital returns



High recurring revenue model



Significant operating leverage



Future growth opportunities distinguishes from EHR peers




Track record of successful capital deployment



Allscripts Healthcare Solutions

JANUARY 2019

J.P. Morgan
Healthcare Conference



Appendix: Non-GAAP Reconciliations

Non-GAAP Financial Measures

This presentation includes references to non-GAAP revenue, non-GAAP earnings per share, Adjusted EBITDA, and free cash flow, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Each of these measures are not considered financial measures under generally accepted accounting principles in the United States ("GAAP"). The definitions of these non-GAAP financial measures are as follows:

- Non-GAAP revenue consists of GAAP revenue, as reported, and adds back recognized deferred revenue from acquired businesses and non-material consolidated affiliates that is eliminated for GAAP purposes due to purchase accounting adjustments.
- Adjusted EBITDA consists of GAAP net income (loss), as reported, and adjusts for: acquisition-related deferred revenue adjustments; depreciation and amortization; stock-based compensation expense; transaction-related and other costs; non-cash asset and long-term investment impairment charges; gain on sale of business, net; interest expense and other, net; equity in net earnings of unconsolidated investments; and tax (benefit) provision.
- Non-GAAP net income consists of GAAP net income/(loss), as reported, and adds back: acquisition-related deferred revenue adjustments; acquisition-related amortization; stock-based compensation expense; transaction-related and other costs; non-cash asset and long-term investment impairment charges; non-cash charges to interest expense and other; gain on sale of business, net; equity in net earnings of unconsolidated investments; and the related tax effect of the aforementioned adjustments. Non-GAAP net income also includes a tax rate alignment adjustment.
- Non-GAAP earnings per share consist of non-GAAP net income, as defined above, divided by weighted average diluted shares outstanding in the applicable period.
- Free cash flow consists of GAAP cash flows provided by operating activities in the applicable period, net of capital expenditures and capitalized software costs.

Management also believes that non-GAAP measures provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein. Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP measures to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, non-GAAP earnings per share, and Adjusted EBITDA are performance measures only, and they do not provide any measure of cash flow or liquidity. Allscripts considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after capital expenditures and capitalized software costs. Free cash flow provides management and investors a valuable measure to determine the quantity of capital generated that can be deployed to create additional shareholder value by a variety of means. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained in the Appendix to this presentation. For the purpose of providing financial guidance, the company does not reconcile non-GAAP revenue, non-GAAP earnings, Adjusted EBITDA or non-GAAP earnings per share guidance to the corresponding GAAP financial measures. Allscripts does not provide guidance for the various reconciling items since certain items that impact GAAP revenue and net income are either outside of its control and/or cannot be reasonably predicted. These are available on Allscripts investor relations website (<http://investor.allscripts.com>).

Reconciliations: Non-GAAP Revenue and Adjusted EBITDA

Allscripts Healthcare Solutions, Inc.
 Non-GAAP Financial Information - Adjusted EBITDA
 (In millions, except percentages)
 (Unaudited)

	Year Ended December 31,				Five Months Ended September 30,
	2014	2015	2016	2017	2018
Total revenue, as reported	\$1,777.9	\$1,886.4	\$1,776.5	\$1,487.2	\$1,300.9
Acquisition-related deferred revenue adjustments	11.6	-	6.6	29.5	23.6
Total non-GAAP revenue excluding NetSmart	\$1,889.5	\$1,886.4	\$1,783.1	\$1,516.7	\$1,324.5
NetSmart	-	-	192.8	226.1	205.9
Total non-GAAP revenue	\$1,889.5	\$1,886.4	\$1,975.9	\$1,742.8	\$1,530.4
Net (loss) income from continuing operations, as reported	(\$64.5)	(\$2.0)	\$20.7	(\$196.6)	\$47.5
Acquisition-related deferred revenue adjustments	11.6	-	6.6	29.5	23.6
Depreciation and amortization	174.2	161.0	139.2	160.6	142.8
Stock-based compensation expense	29.2	26.6	28.6	29.5	20.0
Transaction-related and other costs (a)	24.2	23.6	9.2	21.6	78.4
Interest expense and other, net (b)	15.2	17.6	11.8	19.1	26.0
Asset impairment charges	2.6	1.5	4.7	-	20.1
Impairment of and losses on long-term investments	-	-	7.5	165.3	15.5
Gain on sale of business, net	-	-	-	-	(173.2)
Equity in net (loss) income of unconsolidated investees	-	2.1	-	(0.8)	(0.5)
Tax (benefit) provision	(1.6)	2.6	(1.0)	(6.6)	6.1
Adjusted EBITDA excluding NetSmart	\$199.5	\$242.6	\$246.9	\$175.4	\$227.8
NetSmart	-	-	56.5	98.2	72.5
Adjusted EBITDA	\$199.5	\$242.6	\$303.4	\$273.6	\$300.3
Adjusted EBITDA margin (c)	17%	17%	19%	20%	19%

(a) Transaction-related and other costs has been adjusted from the amounts presented in the reconciliation of GAAP and non-GAAP income from operations, as shown in Table 4, in order to remove the accelerated amortization of assets to be disposed from transaction-related and other costs since such amortization is also included in depreciation and amortization.

(b) Interest expense and other, net has been adjusted from the amounts presented in the statement of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Note and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.

(c) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by non-GAAP revenue.

Reconciliations: Non-GAAP EPS 2017 and 2016

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In million, except per share amounts and percentage)
(Unaudited)

	Year Ended December 31,	
	2017	2016
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders, as reported	\$(196.5)	\$(25.7)
Net (loss) income attributable to non-controlling interest	(1.5)	0.2
Accretion of redemption premium on redeemable convertible non-controlling interest - Nitram	45.8	28.5
Loss (income) from discontinued operations, net of tax	(6.7)	0.0
Net income (loss) from continuing operations, as reported	\$(158.9)	\$3.0
Acquisition-related deferred revenue adjustments	24.5	25.8
Acquisition-related amortization	91.2	71.1
Stock-based compensation expense	41.7	66.2
Transaction-related and other costs (a)	27.4	12.4
Non-cash asset impairment charges	0.0	4.7
Non-cash charges to interest expense and other	12.0	16.6
Impairment of fund lease on long-term investments	165.2	0.0
Equity in net (income)/loss of unconsolidated investments	(0.8)	7.5
Tax effect of adjustments to reconcile GAAP to non-GAAP net income	(140.2)	(64.1)
Tax rate alignment	22.6	(12.8)
Total Non-GAAP net income	\$124.8	\$109.6
Less: Non-GAAP net income attributable to non-controlling interest	(11.9)	(5.5)
Non-GAAP net income attributable to Allscripts Healthcare Solutions, Inc.	\$112.9	\$104.1
Non-GAAP effective tax rate	25%	25%
Weighted average outstanding - diluted	182.5	187.9
(Loss) earnings per share - basic and diluted, as reported	\$(1.09)	\$(0.14)
Non-GAAP earnings per share attributable to Allscripts Healthcare Solutions, Inc. - diluted	\$0.62	\$0.55

Note: Adjustments to reconcile GAAP to non-GAAP net income are presented gross of tax, with net tax effects included in row titled "Tax effect of adjustments to reconcile GAAP to non-GAAP net income".
(a) Transaction-related and other costs included in cost of revenue, operating expenses and non-operating expenses are comprised of the following for the periods presented:

	Year Ended December 31,	
	2017	2016
Legal and other costs	29.7	2.7
Transaction-related costs	27.7	10.7
Total transaction-related and other costs	\$57.4	\$13.4

Reconciliations: Non-GAAP EPS 2015

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per share amounts and percentages)
(Unaudited)

	Year Ended December 31, 2015
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders, as reported	\$(22)
Less: Net loss attributable to non-controlling interest	0.0
Less: Acquisition of ownership preference on convertible non-controlling interest - Novartis	0.0
Net income (loss), as reported	\$(22)
Acquisition-related financial review adjustments	0.0
Acquisition-related amortization	282
Stock-based compensation expense	266
Non-recurring expense and transaction-related costs (a)	224
Non-cash asset impairment charge	1.5
Non-cash disposal income expense and other	120
Equity in net earnings of an unaffiliated investment	2.2
Tax effect of adjustments to reconcile GAAP to non-GAAP net income	(174)
Tax rate adjustment	2.5
Total Non-GAAP net income	\$211
Less: Non-GAAP net income attributable to non-controlling interest	(81)
Non-GAAP net income attributable to Allscripts Healthcare Solutions, Inc.	\$230
Non-GAAP effective tax rate	26%
Weighted shares outstanding - diluted	184.5
(Loss) earnings per share - basic and diluted, as reported	\$(0.01)
Non-GAAP earnings per share attributable to Allscripts Healthcare Solutions, Inc. - diluted	\$0.47

Notes: Adjustments to reconcile GAAP to non-GAAP net income are presented gross of tax, with a net tax effect included in reconciling "Tax effect of adjustments to reconcile GAAP to non-GAAP net income".

(a) Non-recurring expenses and transaction-related costs included in cost of revenue and operating expenses are comprised of the following for the reporting period:

	Year Ended December 31, 2015
Systemic and other costs	222
Transaction-related costs	0.1
Total non-recurring expenses and transaction related costs	\$224

Reconciliations: Free Cash Flow

Allscripts Healthcare Solutions, Inc.	
Condensed Non-GAAP Financial Information - Free Cash Flow	
(In millions)	
(Unaudited)	
	1/1/2014 - 9/30/2018
	<u>TOTAL</u>
Net cash provided by operating activities	\$945.1
Cash flows from investing activities:	
Capital expenditures	(153.2)
Capitalized software	<u>(432.7)</u>
Free cash flow	<u>\$359.2</u>

